Rosetta to Delay Certain miRNA Diagnostics as It Markets Certain Others Itself
April 07, 2011
Rosetta to Delay Certain miRNA Diagnostics as It Markets Certain Others Itself
The company is aiming to market two of its miRNA diagnostics in the US on its own, and will delay the launch of certain other next-generation tests as a result.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Stock Rises on Reverse Stock Split, Kidney Test Launch, Medicare Coverage of CUP Dx
May 17, 2012 / Gene Silencing News - Rosetta Staves off Bankruptcy with Payment to Former Marketing Partner Prometheus
December 8, 2011 / Gene Silencing News - Rosetta Defaults on Payment to Prometheus, Faces Bankruptcy
December 1, 2011 / Gene Silencing News - Rosetta Regains US Rights to miRNA Cancer Diagnostics, Addresses QC Issue at Diagnostics Lab
December 2, 2010 / Gene Silencing News - Rosetta Genomics Unveils Two New Development-Stage Tests
September 9, 2010 / Gene Silencing News